Neurotoxicology and Teratology 2002-01-01

Assessing the potential toxicity of MK-801 and remacemide::Chronic exposure in juvenile rhesus monkeys

E.J Popke, R Patton, G.D Newport, L.G Rushing, C.M Fogle, R.R Allen, E.C Pearson, T.G Hammond, M.G Paule, E J Popke, R Patton, G D Newport, L G Rushing, C M Fogle, R R Allen, E C Pearson, T G Hammond, M G Paule

Index: Neurotoxicol. Teratol. 24(2) , 193-207, (2002)

Full Text: HTML

Abstract

The present experiment examined the effects of chronic exposure to either 0.1 or 1.0 mg/kg MK-801 [a selective N-methyl- d-aspartate (NMDA) receptor antagonist] or 20.0 or 50.0 mg/kg remacemide (an NMDA receptor antagonist which also blocks fast sodium channels) in juvenile rhesus monkeys. Endpoints were monitored to provide a general index of subjects' health and included measures of clinical chemistry, hematology, ophthalmology, spontaneous home-cage behavior, and peak drug plasma levels. In general, both drugs were well tolerated and produced no treatment-related effects during 2 years of dosing and assessment. Periodic plasma drug level determinations provided limited evidence that both compounds may induce their own metabolism. The present results contrast sharply with previously reported effects of long-lasting impairments in the acquisition of incremental learning and in the development of color and position discrimination in these same subjects. These observations highlight the importance of collecting a broad range of toxicology data, including tests of cognitive function, to make comprehensive assessments of new drug safety. In the present case, the less obvious effects of these drugs on cognition defined the toxicologic response.


Related Compounds

Related Articles:

The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy.

2009-03-01

[Epilepsy Behav. 14(3) , 522-8, (2009)]

Chronic exposure to NMDA receptor and sodium channel blockers during development in monkeys and rats: long-term effects on cognitive function.

2003-05-01

[Ann. N. Y. Acad. Sci. 993 , 116-22; discussion 123-4, (2003)]

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.

2001-11-27

[Neurosci. Lett. 315(3) , 149-53, (2001)]

Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study.

2003-08-01

[Exp. Neurol. 182(2) , 461-9, (2003)]

Behavioral effects associated with chronic ketamine or remacemide exposure in rats.

2007-01-01

[Neurotoxicol. Teratol. 29(3) , 348-59, (2007)]

More Articles...